HollyF.LoftonMDDABOM

Internal Medicine • New York, NY

Obesity Medicine & Nutrition

Clinical Associate Professor, Medicine and Surgery, New York University School of Medicine, Director, Medical Weight Management Program

Join to view full profile

Dr. Lofton is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Lofton's full profile

Already have an account?

Office
530 1st Avenue
Suite 10S
New York, NY 10016

Education & Training

Geisinger Health SystemFellowship, Obesity Medicine and Nutrition Support, 2007 - 2008
Zucker School of Medicine at Hofstra/Northwell at Lenox Hill HospitalResidency, Internal Medicine, 2005 - 2007
Medical College of GeorgiaInternship, Internal Medicine, 2004 - 2005
Medical College of Georgia at Augusta UniversityClass of 2004

Certifications & Licensure

FL State Medical License 2020 - Present
NY State Medical License 2010 - 2026
NJ State Medical License 2024 - 2025
PA State Medical License 2007 - 2016
American Board of Internal Medicine Internal Medicine
American Board of Obesity Medicine Obesity Medicine

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013

Clinical Trials

Clinical Efficacy and Safety of Using 3.0mg Liraglutide to Treat Weight Regain After Roux-en-Y Gastric Bypass Surgery Start of enrollment: 2017 May 22
Completed
Phase 4
A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity Start of enrollment: 2022 Oct 11
Active, not recruiting
Phase 3
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight Start of enrollment: 2019 Dec 04
Active, not recruiting
Phase 3

Publications & Presentations

PubMed

Lightening the Load: Generative AI to Mitigate the Burden of the New Era of Obesity Medical Therapy.
Elizabeth R Stevens, Arielle Elmaleh-Sachs, Holly Lofton, Devin M Mann
JMIR Diabetes. 2024-11-14
A randomized, double-blind, placebo-controlled trial of weight loss using liraglutide 3.0 mg for weight recurrence after Roux-en-Y gastric bypass.
Holly F Lofton, Gabrielle Maranga, Robert Hold, George Fielding, Heekoung Youn
Surgery for Obesity and Related Diseases. 2024-09-10
Obesogenic Medication Use in End-Stage Kidney Disease and Association With Transplant Listing.
Babak J Orandi, Yiting Li, Timur Seckin, Sunjae Bae, Bonnie E Lonze
Clinical Transplantation. 2024-08-01

Press Mentions

Focus: Doctors Struggle to Get Wegovy for Older Americans with Heart DiseaseAugust 15th, 2024
Ozempic Could Be an Accidental Treatment for AddictionMay 24th, 2023
How Obesity and Metabolic Health Can Impact Your Cancer RiskMay 16th, 2023
Join now to see all